The healthcare stock winning from COVID-19
A New Zealand healthcare firm is one of the few stocks to see a material increase in its share price in light of COVID-19.
Fisher & Paykel Healthcare, which was based in New Zealand but listed on the ASX in 2001, had seen its share price rise 9.8% year to date to 12 March. This is a sharp contrast to the stock market performance of the ASX 200 which had fallen 19.7% over the same period.
The firm produced respiratory equipment such as humidifiers, as well as disposable medical equipment such as chambers and breathing circuits, used to deliver gases received during ventilation.
Its flagship product was a respiratory humidifier for patients who were being ventilated in intensive care.
Founded in 1934 in Auckland, its share price has risen by 325% in the past five years compared to returns of 22.9% by the ASX 200, according to FE Analytics.
Stephen Wood, manager of the $5.6 million Eiger Australian Small Companies fund, said: “Fisher & Paykel produces respiratory equipment and consumables which can only be used once. The boost to the business will be more than shortlived and it could give the business a big step-up.
“Healthcare firms will do well and see increased activity, they are defensive stocks so are less reliant on consumer spending.”
It is also known for producing kitchen appliances such as washing machines, ovens and fridges under a separate company Fisher & Paykel Appliances.
Share price of Fisher & Paykel Healthcare year to date versus ASX 200
AUTHOR
Laura Dew
Recommended for you
Women are expected to inherit US$124 trillion through the intergenerational wealth transfer, but Capital Group has found they are twice as likely to rely on social media for advice over a financial adviser.
Challenger Investment Management has raised $350 million during the offer period for its new ASX-listed investment structure.
A week after Lonsec downgraded multiple funds from Metrics Credit Partners, rival research house Zenith Investment Partners has opted to retain its ratings for the same funds.
Strong adviser engagement has helped Praemium reach $1 billion in inflows on its Spectrum offering, with a deal with Western Australian wealth firm Euroz Hartleys expected to add as much as $2 billion.
